Title |
Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720
|
---|---|
Published in |
EPMA Journal, January 2014
|
DOI | 10.1186/1878-5085-5-3 |
Pubmed ID | |
Authors |
Shawn Baldacchino, Christian Saliba, Vanessa Petroni, Anthony G Fenech, Nigel Borg, Godfrey Grech |
Abstract |
The most commonly used biomarkers to predict the response of breast cancer patients to therapy are the oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). Patients positive for these biomarkers are eligible for specific therapies such as endocrine treatment in the event of ER and PgR positivity, and the monoclonal antibody, trastuzumab, in the case of HER2-positive patients. Patients who are negative for these three biomarkers, the so-called triple negatives, however, derive little benefit from such therapies and are associated with a worse prognosis. Deregulation of the protein serine/threonine phosphatase type 2A (PP2A) and its regulatory subunits is a common event in breast cancer, providing a possible target for therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 62 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 17 | 27% |
Student > Master | 14 | 23% |
Student > Bachelor | 10 | 16% |
Researcher | 6 | 10% |
Student > Doctoral Student | 2 | 3% |
Other | 6 | 10% |
Unknown | 7 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 21 | 34% |
Agricultural and Biological Sciences | 14 | 23% |
Medicine and Dentistry | 12 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Computer Science | 2 | 3% |
Other | 4 | 6% |
Unknown | 7 | 11% |